Tag: NYSEMKT:RNN

Gilead Sciences GILD NASDAQ:GILD
Finance

Biotech Losers: MannKind Corporation (NASDAQ:MNKD), Rexahn Pharmaceuticals (NYSEMKT:RNN), ZIOPHARM Oncology (NASDAQ:ZIOP), Seattle Genetics (NASDAQ:SGEN)

MannKind Corporation (NASDAQ:MNKD) announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for AFREZZA(R) by three months to July 15, 2014 in order to provide time for a full review of information submitted by MannKind in response to the FDA’s requests.MannKind Corporation (NASDAQ:MNKD) stock performance was -6.42% in last session and finished the day at … Continue reading Biotech Losers: MannKind Corporation (NASDAQ:MNKD), Rexahn Pharmaceuticals (NYSEMKT:RNN), ZIOPHARM Oncology (NASDAQ:ZIOP), Seattle Genetics (NASDAQ:SGEN)

Kristen Barton
Finance

Micro-cap Active runners: CytRx Corporation (NASDAQ:CYTR), Response Genetics (NASDAQ:RGDX), Catalyst Pharmaceutical Partners (NASDAQ:CPRX), Rexahn Pharmaceuticals (NYSEMKT:RNN)

CytRx Corporation (NASDAQ:CYTR) seeks to present the detailed results of the positive outcome from the study which was conducted in an animal representation of glioblastoma at the AACRAM which will be held from between April 5 and April 9 in San Diego, CA. CytRx Corporation (NASDAQ:CYTR) stock performance was 3.67% in last session and finished the day at $3.95. Traded volume was 11.77million shares in … Continue reading Micro-cap Active runners: CytRx Corporation (NASDAQ:CYTR), Response Genetics (NASDAQ:RGDX), Catalyst Pharmaceutical Partners (NASDAQ:CPRX), Rexahn Pharmaceuticals (NYSEMKT:RNN)

Mark DeFrance
Finance

Biotech Active Movers: Ariad Pharmaceuticals (NASDAQ:ARIA), Insmed Incorporated (NASDAQ:INSM), Rexahn Pharmaceuticals (NYSEMKT:RNN), Inovio Pharmaceuticals (NYSEMKT:INO)

Earlier this week, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that it has initiated a phase II pivotal study that will evaluate the safety and efficacy of AP26113 in locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients who had previously been treated with Pfizer’s (PFE – Analyst Report) Xalkori (crizotinib). Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock performance was -1.16% in last session and finished the … Continue reading Biotech Active Movers: Ariad Pharmaceuticals (NASDAQ:ARIA), Insmed Incorporated (NASDAQ:INSM), Rexahn Pharmaceuticals (NYSEMKT:RNN), Inovio Pharmaceuticals (NYSEMKT:INO)

Jayne Crisman
Finance

Biotech Active Runners: Hemispherx BioPharma (NYSEMKT:HEB), Rexahn Pharmaceuticals (NYSEMKT:RNN), Arena Pharmaceuticals (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA)

Hemispherx Biopharma, Inc. (NYSE MKT:HEB) participated in the 11th Biennial International Research and Clinical Conference  held in San Francisco, California, USA, March 20-23, 2014. The title of the presentation is “Differential Exercise Responses to Rintatolimod [Ampligen(R)] Exhibited by Patients with Severe Chronic Fatigue Syndrome (CFS)”. This Phase III prospective, double-blind, randomized, placebo-controlled trial was conducted at twelve centers by leading researchers in fatigue and post-exertional … Continue reading Biotech Active Runners: Hemispherx BioPharma (NYSEMKT:HEB), Rexahn Pharmaceuticals (NYSEMKT:RNN), Arena Pharmaceuticals (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA)

Jason Knox
Finance

Biotech Active Runners: Galena Biopharma Inc. (NASDAQ:GALE), Gilead Sciences (NASDAQ:GILD), Rexahn Pharmaceuticals (NYSEMKT:RNN), Inovio Pharmaceuticals Inc. (NYSEMKT:INO)

Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Oregon on behalf of holders of Galena Biopharma, Inc. (NASDAQ:GALE) securities between November 6, 2013 and February 14, 2014. Galena Biopharma Inc. (NASDAQ:GALE) stock performance was -12.42% in last session and finished the day at $2.82. Traded volume was 17.65 million shares in … Continue reading Biotech Active Runners: Galena Biopharma Inc. (NASDAQ:GALE), Gilead Sciences (NASDAQ:GILD), Rexahn Pharmaceuticals (NYSEMKT:RNN), Inovio Pharmaceuticals Inc. (NYSEMKT:INO)

Colin Pettis
BioTech

Biotech Top Losers: Rexahn Pharmaceuticals (NYSEMKT:RNN), Aegerion Pharmaceuticals (NASDAQ:AEGR), Enzymotec Ltd (NASDAQ:ENZY), Can Fite Biopharma (NYSEMKT:CANF)

Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) was a big mover last session, as its shares rose nearly 11% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the trend for the healthcare company since Feb 24, as the stock is now down nearly 19%. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) dropped -5.53 percent to $52.46 … Continue reading Biotech Top Losers: Rexahn Pharmaceuticals (NYSEMKT:RNN), Aegerion Pharmaceuticals (NASDAQ:AEGR), Enzymotec Ltd (NASDAQ:ENZY), Can Fite Biopharma (NYSEMKT:CANF)

Kristen Barton